The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study

Karine Cavalcanti Maurício Sena-Evangelista, Lucia Fatima Campos Pedrosa, Maria Sanali Moura Oliveira Paiva, Paula Cristina Silveira Dias, Diana Quitéria Cabral Ferreira, Sílvia Maria Franciscato Cozzolino, Tanize Espírito Santo Faulin, Dulcinéia Saes Parra Abdalla, Karine Cavalcanti Maurício Sena-Evangelista, Lucia Fatima Campos Pedrosa, Maria Sanali Moura Oliveira Paiva, Paula Cristina Silveira Dias, Diana Quitéria Cabral Ferreira, Sílvia Maria Franciscato Cozzolino, Tanize Espírito Santo Faulin, Dulcinéia Saes Parra Abdalla

Abstract

Objective: Statins treatment may modify the levels of zinc and selenium, minerals that can improve vascular function and reduce oxidative damage and inflammation in atherosclerotic patients. This study aimed to evaluate the effects of rosuvastatin, alone or associated with zinc and selenium supplementation, on lipid profile, antioxidant enzymes and mineral status in coronary artery disease patients.

Material and methods: A double-blind randomized clinical trial was performed in which patients (n = 76) were treated with 10 mg rosuvastatin over 4 months associated or not with zinc (30 mg/d) and selenium (150 μg/d) supplementation. The following parameters were analyzed before and after the intervention: anthropometric measurements, lipid profile, high sensitivity C-reactive protein (hs-CRP), electronegative low density lipoprotein (LDL(-)) concentrations, activities of glutathione peroxidase (GPx), superoxide dismutase (SOD), zinc and selenium concentrations in blood plasma and erythocytes. Significance was determined using an α of 5% (two-tailed).

Results: We found that rosuvastatin therapy was efficient in reducing total cholesterol, LDL-cholesterol, non-HDL cholesterol, triglycerides, and hs-CRP independently of mineral supplementation. Neither treatment was associated with significant changes in LDL(-). Similarly, the antioxidant enzymes GPx and SOD activity were unchanged by treatments. Neither treatment was associated with significant differences in concentrations of zinc or selenium in blood plasma and erythocytes of studied groups.

Conclusion: Rosuvastatin treatment did not affect zinc and selenium levels in coronary artery disease patients. The zinc and selenium supplementation at doses used in this study did not change lipid profile or SOD and GPx activity in patients receiving rosuvastatin. Further studies should be focused on testing alternative doses and supplements in different populations to contribute for a consensus on the ideal choice of antioxidants to be used as possible complementary therapies in atherosclerotic patients.

Trial registration: ClinicalTrials.gov NCT01547377.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flow diagram demonstrating participants flow…
Fig 1. Flow diagram demonstrating participants flow through the study.
Fig 2. Flow chart describing the monitoring…
Fig 2. Flow chart describing the monitoring of patients.

References

    1. Little PJ, Bhattacharya R, Moreyra AE, Korichneva IL. Zinc and cardiovascular disease. Nutrition. 2010; 26: 1050–7. 10.1016/j.nut.2010.03.007
    1. Tanguy S, Grauzam S, de Leiris J, Boucher F. Impact of dietary selenium intake on cardiac health: Experimental approaches and human studies. Mol Nutr Food Res. 2012; 56: 1106–21. 10.1002/mnfr.201100766
    1. Beattie JH, Kwun IN. Is zinc deficiency a risk factor for atherosclerosis? Br J Nutr. 2004; 91:177–81.
    1. Zhang F, Yu W, Hargrove JL, Greenspan P, Dean RG, Taylor EW, et al. Inhibition of TNF-alpha induced ICAM-1, VCAM-1 and E-selectin expression by selenium. Atherosclerosis. 2002; 161:381–86.
    1. Leonhardt W, Kurktschiev T, Meissner D, Lattke P, Abletshauser C, Weidinger G, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol. 1997; 53: 65–9.
    1. Yilmaz MI, Baykal Y, Kilic M, Sonmez A, Bulucu F, Aydin A, et al. Effects of statins on oxidative stress. Biol Trace Elem Res. 2004; 98: 119–27.
    1. Moosman B, Behl C. Selenoproteins, cholesterol-lowering drugs and the consequences. Trends Cardiovascul Med. 2004; 14: 273–81.
    1. Arnaud J, Akbaraly T, Hinninger I, Berr C, Roussel AM. Fibrates but not statins increase plasma selenium in dyslipidemic aged patients—The EVA study. J Trace Elem Med Biol. 2009; 23: 21–8. 10.1016/j.jtemb.2008.08.001
    1. Lim SY. Role of statins in coronary artery disease. Chonnam Med J. 2013; 49:1–6. 10.4068/cmj.2013.49.1.1
    1. Ghayour-Morbarhan M, Lamb DJ, Taylor A, Vaidya N, Livingstone C, Wang T, Ferns GAA. Effect of statin therapy on serum trace element status in dyslipidemic subjects. J Trace Elem Med Biol. 2005; 19: 61–7.
    1. Alexander DD, Weed DL, Chang ET, Miller PE, Mohamed MA, Elkayam LA. A systematic review of multivitamin-multimineral use and cardiovascular disease and cancer incidence and total mortality. J Am Coll Nutr. 2013;32(5):339–54. 10.1080/07315724.2013.839909
    1. Mocchegiani E, Malavolta M, Muti E, Costarelli L, Cipriano C, Piacenza F, et al. Zinc, metallothioneins and longevity: interrelationships with niacin and selenium. Curr Pharm Des. 2008; 14: 2719–32.
    1. Third Report of the National Cholesterol Education Program NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143–421.
    1. Faulin TES, Sena KCM, Telles AER, Grosso DM, Faulin EJB, Abdalla DSP. Validation of a novel ELISA for measurement of electronegative low density lipoprotein. Clin Chem Lab Med. 2008; 46: 1769–75. 10.1515/CCLM.2008.333
    1. Sena KCM, Arrais RF, Almeida MG, de Araújo DM, dos Santos MM, de Lima VT, et al. Effects of zinc supplementation in patients with type 1 Diabetes. Biol Trace Elem. 2005; 105: 1–9.
    1. Hao D, Xie G, Zhang Y, Tian G. Determination of serum selenium by hydride generation flame atomic absorption spectrometry. Talanta 1996;43:595–600.
    1. Luz PL, Cesena FH, Favarato D, Cerqueira ES. Comparison of serum lipid values in patients with coronary artery disease at <50, 50 to 59, 60 to 69, and >70 years of age. Am J Cardiol. 2005;96(12):1640–3.
    1. Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004;25:1880–1890.
    1. Hu DY, Pan CY, Yu JM, China Heart Survey Group. The relationship between coronary artery disease and abnormal glucose regulation in China: the China Heart Survey. Eur Heart J. 2006. Nov;27(21):2573–9.
    1. Taubert G, Winkelmann BR, Schleiffer T, März W, Winkler R, Gök R, et al. Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography. Am Heart J. 2003. Feb;145(2):285–91.
    1. Schuster H. Rosuvastatin- a highly effective new 3-hydroxy-e-methyglutaryl coenzyme A reductase inhibitor: review of clinical Trial data at 10–40mg doses in dyslipidemics patients. Cardiology. 2003; 99: 126–39.
    1. Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag. 2009; 5: 343–52.
    1. Oliveira JA, Sevanian A, Rodrigues RJ, Apolinário E, Abdalla DSP. Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes. Clin Biochem 2006; 39:708–14.
    1. Pereira EC, Bertolami MC, Faludi AA, Sevanian A, Abdalla DSP. Antioxidant effect of simvastatin is not enhanced by its association with α-tocopherol in hypercholesterolemic patients. Free Rad Biol & Med. 2004; 37: 1440–8.
    1. Prasad AS. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc. Exp Gerontol. 2008; 43: 370–7.
    1. Tinggi U. Selenium: its role as antioxidant in human health. Environ Health Prev Med. 2008; 13: 102–108. 10.1007/s12199-007-0019-4
    1. Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev. 2006; 15: 804–10.
    1. Gómez-García A, Torres GM, Ortega-Pierres LE, Rodríguez-Ayalla E, Álvarez-Aguillar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev. Esp. Cardiol. 2007; 60: 1242–49.
    1. Andersen HR, Nielsen JB, Nielsen F, Grandjean P. Antioxidative enzyme activities in human erythrocytes. Clin Chem. 1997; 43: 562–8.
    1. Feillet-Coudray C, Meunier N, Bayle D, Brandolini-Bunlon M, Andriollo-Sanchez M, O'Connor JM, et al. Effect of zinc supplementation on in vitro copper-induced oxidation of low-density lipoproteins in healthy French subjects aged 55–70 years: the Zenith Study. Br J Nutr. 2006; 95: 1134–42.
    1. Prasad AS, Bao B, Beck FWJ, Kucuk O, Sarkarz FH. Antioxidant effect of zinc in humans. Free Rad Biol Med. 2004; 37: 1182–90.
    1. Papp LV, Lu J, Holmgren A, Khanna KK. Selenium and selenoproteins in health and disease. Antioxid Redox Signal. 2010; 12: 793–5. 10.1089/ars.2009.2973
    1. Roussel AM, Kerkeni A, Zouari N, Mahjoub S, Matheau JM, Anderson RA. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus. J Am Coll Nutr. 2003; 22: 316–21.
    1. Cragg RA, Phillips SR, Piper JM, Varma JS, Campbell FC, Mathers JC, et al. Homeostatic regulation of zinc transporters in the human small intestine by dietary zinc supplementation. Gut. 2005; 54: 469–78.
    1. Johnson F, Giulivi C. Superoxide dismutases and their impact upon human health. Mol Aspects Med. 2005; 26: 340–52.
    1. Farrokhi F, Moohebati M, Aghdaei HR, Ghaffarzadegan K, Norouzi F, Sahebkar A, et al. Effects of Statin Therapy on Serum Trace Element Status in Dyslipidemic Patients: Results of a Randomized Placebo-Controlled Cross-Over Trial. Clin Lab. 2012; 58: 1005–15.
    1. Costarelli L, Muti E, Malavolta M, Giacconi R, Cipriano C, Sartini D, et al. Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors. Rejuvenation Res. 2008; 11: 287–91. 10.1089/rej.2008.0665
    1. Seet RC, Lee CY, Lim EC, Quek AM, Huang H, Huang SH, et al. Oral zinc supplementation does not improve oxidative stress or vascular function in patients with type 2 diabetes with normal zinc levels. Atherosclerosis. 2011; 219: 231–39. 10.1016/j.atherosclerosis.2011.07.097
    1. Mariani E, Mangialasche F, Feliziani FT, Cecchetti R, Malavolta M, Bastiani P, et al. Effects of zinc supplementation on antioxidant enzyme activities in healthy old subjects. Exp Gerontol. 2008; 43: 445–51.
    1. Nève J, Hanocq M, Peretz A, Khalil A, Pelen F. Some factors influencing the bioavailability of zinc in oral pharmaceutical dosage forms. J Pharm Belg. 1993; 48: 5–11.
    1. Fairweather-Tait S, Collings R, Hurst R. Selenium bioavailability: current knowledge and future research requirements. Am J Clin Nutr. 2010; 91: 1484S–91S. 10.3945/ajcn.2010.28674J
    1. Ashton K, Hooper L, Harvey LJ, Hurst R, Casgrain A, Fairweather-Tait SJ. Methods of assessment of selenium status in humans: a systematic review. Am J Clin Nutr. 2009; 89: 2025S–39S. 10.3945/ajcn.2009.27230F
    1. Bruckdorfer KR. Antioxidants and CVD. Proc Nutr Soc. 2008; 67:214–22. 10.1017/S0029665108007052
    1. Kaliora AC, Schmidt DH. Dietary antioxidant in preventing atherogenesis. Atherosclerosis. 2006; 187:1–17.
    1. Otero-Losada M, Vila S, Azzato F, Milei J. Antioxidants supplementation in elderly cardiovascular patients. Oxid Med Cell Longev. 2013;2013:408260 10.1155/2013/408260

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere